Navigation Links
Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference
Date:10/18/2007

HOPKINTON, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Dr. Frank Bobe, Executive Vice President and Chief Business Officer of Alseres Pharmaceuticals, Inc., will be presenting at Windhover Information's 2nd Annual Therapeutic Area Partnerships in Philadelphia, PA October 24-26, 2007. Dr. Bobe will be presenting an overview on Alseres Regenerative Therapeutics program. Cethrin(R), the Company's lead regenerative therapeutic for acute spinal cord injury, was named one of the "Top 10 Licensable Neuroscience Projects" by Windhover.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Windhover Information's 2nd Annual Therapeutic Area Partnerships is the industry's most targeted and efficient partnering meeting for life science companies seeking partnerships in the top therapeutic areas: Oncology, Cardiovascular/Metabolic and Neuroscience. Decision-makers (business development and R & D) focusing on these therapeutic categories can meet to develop strategic alliances between their companies. For more information on the conference and speaking companies please go to http://www.tapartnerships.com .

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... management and analytics solutions, today announced that its Anzo Smart Data Lake® ... 2017 Software & Information Industry Association (SIIA) CODiE Awards. , Cambridge Semantics’ ...
(Date:7/26/2017)... Brea, Ca (PRWEB) , ... July 25, 2017 ... ... labels, specialty converted media and software solutions that enable short-run digital printing, is ... GHS Chemical Labels and its free GHS Wizard online software available at ...
(Date:7/26/2017)... ... July 25, 2017 , ... The ... that its regenerative stem cell therapy has been used on more than 13,000 ... for horses with potentially fatal injuries to tendons and ligaments. , In 2003 ...
(Date:7/26/2017)... ... July 25, 2017 , ... Provia Laboratories ... in the preparation and development of human cells and tissues for therapeutic use. ... Food and Drug Administration’s (FDA) Current Good Manufacturing Practices (cGMP) guidelines and provides ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):